Importantly, these fluctuations can be therapeutically targeted: deacetylase inhibitors restore SLFN11 expression, reactivating its tumor-suppressive functions and sensitizing resistant cancer cells to DNA-damaging treatments (Table 1). This evidence concerns the gene SLFN11 and neoplasm.